Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination With Defactinib for the Treatment of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
Verastem腫瘤學宣佈FDA接受並優先審查Avutometinib與Defactinib聯合治療複發性Kras突變低級別漿液性卵巢癌的新藥申請
